Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
Condition: Autosomal-dominant Hyper-IgE Syndrome
Intervention: Drug: NDV-3A
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 18, 2016
Intervention: Drug: NDV-3A
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 18, 2016
News Type: